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Summary
Crigler-Najjar syndrome type 1 (CN-1) is a recessively
inherited, potentially lethal disorder characterized by se-
vere unconjugated hyperbilirubinemia resulting fromde-
ficiency of the hepatic enzyme bilirubin-UDP-glucuron-
osyltransferase. In all CN-1 patients studied, structural
mutations in one of the five exons of the gene (UGT1A1)
encoding the uridinediphosphoglucuronate glucurono-
syltransferase (UGT) isoform bilirubin-UGT1 were im-
plicated in the absence or inactivation of the enzyme.
We report two patients in whomCN-1 is caused, instead,
by mutations in the noncoding intronic region of the
UGT1A1 gene. One patient (A) was homozygous for a
GrC mutation at the splice-donor site in the intron,
between exon 1 and exon 2. The other patient (B) was
heterozygous for an ArG shift at the splice-acceptor site
in intron 3, and in the second allele a premature trans-
lation-termination codon in exon 1 was identified. Bil-
irubin-UGT1 mRNA is difficult to obtain, since it is ex-
pressed in the liver only. To determine the effects of these
splice-junction mutations, we amplified genomic DNA
of the relevant splice junctions. The amplicons were ex-
pressed in COS-7 cells, and the expressed mRNAs were
analyzed. In both cases, splice-site mutations led to the
use of cryptic splice sites, with consequent deletions in
the processed mRNA. This is the first report of intronic
mutations causing CN-1 and of the determination of the
consequences of these mutations on mRNA structure,
by ex vivo expression.
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Introduction
Bilirubin, a toxic breakdown product of heme, is insol-
uble in water because of internal hydrogen bonding.
Uridinediphosphoglucuronate glucuronosyltransferase
(UGT), a family of enzymes located in the membrane of
the endoplasmic reticulum (Roy Chowdhury et al.
1985), transfers the glucuronic acid moiety from uri-
dinediphosphoglucuronate to bilirubin, as well as a wide
variety of other endogenous compounds and xenobiot-
ics. Glucuronidation converts these substrates to polar
conjugates that are readily excreted in bile or urine (Dut-
ton 1980). A specific UGT isoform mediates the glu-
curonidation of bilirubin (bilirubin-UGT1) (Bosma et al.
1994). UGT activity toward bilirubin is essential for the
efficient biliary excretion of bilirubin. Inherited abnor-
malities of this enzyme (Schmidt et al. 1958; Arias et al.
1969) result in the potentially lethal Crigler-Najjar syn-
drome type I (Crigler and Najjar 1952), which is char-
acterized by the accumulation of unconjugated bilirubin
in the plasma.
Bilirubin-UGT1, also designated “UGT1A1,” is en-
coded by five consecutive exons located at the 3′ end of
the UGT1A locus (Ritter et al. 1992a;Mackenzie 1997)
and is expressed in the liver only. In recent studies,
a large number of different Crigler-Najjar syn-
drome–causing mutations in the exons encoding the
UGT1A1 gene have been reported (Bosma et al. 1992a,
1992b; Ritter et al. 1992b; Moghrabi et al. 1993a,
1993b; Labrune et al. 1994; Seppen et al. 1994).
In this study, we report two cases in which intronic
mutations result in bilirubin-UGT deficiency. UGT1A1
is expressed in the liver only. Liver material of most
patients is not available. Therefore, the effect of these
mutations on the processing of UGT1A1 gene tran-
scripts was determined by ex vivo expression studies.
We show that these ex vivo studies can be used to con-
firm the effect of intronic mutations on the structure of
UGT1A1 mRNA.
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Subjects and Methods
Case History
Patient A is an 18-mo-old boy who has had jaundice
continuously since 48 h after birth. Serum bilirubin at
72 h after birth was 30 mg/dl (510 mM), and photo-
therapy was instituted. Bile was analyzed by reverse-
phase high-pressure liquid chromatography and showed
that only trace amounts of bilirubin monoglucuronide
were present and that 195% of the bile pigments were
unconjugated bilirubin. A 2-wk course of phenobarbital
therapy reduced serum bilirubin levels by 15%. Cur-
rently, while the patient is being treated by phototherapy,
but without phenobarbital, the serum bilirubin levels
have been 18–26 mg/dl (306–442 mM), all of which has
been found to be unconjugated, by chromatographic
analysis. There is no evidence of neurotoxicity.
Patient B is a 25-year-old man who also has been
continuously icteric since birth. All of the serumbilirubin
was unconjugated. No bilirubin glucuronides were de-
tectable in bile. There was no appreciable reduction of
serum bilirubin levels by phenobarbital therapy. His se-
rum bilirubin levels were maintained at 20–24 mg/dl
(340–408 mM) by intensive phototherapy. However, dur-
ing a period of noncompliance, serum bilirubin concen-
trations were 130 mg/dl (1510 mM). After an episode
of acute neurotoxicity, the patient began to show mild
ataxia. Therefore, an orthotopic liver transplant was
performed, and the patient was placed on immunosup-
pressive therapy. Serum bilirubin concentrations were
normalized 48 h after the liver transplant and have re-
mained normal since. Currently, the patient is
asymptomatic.
Nucleotide-Sequence Analysis
Genomic DNA was isolated from whole blood by use
of the QIAamp blood kit (Qiagen) according to the man-
ufacturer’s instructions. All five exons constituting the
coding region of bilirubin-UGT1 and the flanking in-
tronic regions were amplified by PCR, as described else-
where (Bosma et al. 1992a). In patient A, the nucleotide
sequence of the amplicons was determined by cycle se-
quencing without cloning. In patient B, the amplicons
were cloned before sequencing. Sequence determination
was performed on three different PCR products, for both
strands.
Minigene Construction
Genomic DNA samples of both patients and of several
normal individuals were amplified by PCR using am-
plimer pairs as shown in figure 1. PCR was performed
for 35 cycles consisting of denaturation at 95C for 30
s, annealing at 56C for 30 s, and extension at 72C for
1 min. Final extension was at 72C for 5 min. The con-
centration of MgCl2 was 1.5 mM. Amplified DNA frag-
ments were purified by use of the Qiagen PCR purifi-
cation kit according to the manufacturer’s instructions.
Two PCR fragments were amplified from genomic
DNA of patient A and of a normal individual, by use
of primers 1S and 1AS and primers 2S and 2AS, re-
spectively. The BglII sites present in primers 1AS and 2S
were used to combine both amplicons. By ligation, prim-
ers 3S and 3AS were used to generate the minigene,
which contained the 3′ end of UGT1A1 exon 1; the 5′
region of intron 1; and exons 2–4; and introns 2 and 3.
The minigene was cloned into the eukaryotic expression
vector pCMV-LIC (Pharmingen), downstream of a cy-
tomegalovirus early region promoter. The expression
vector containing the splice-acceptor–site mutation of
patient B, at the 3′ end of intron 3, was produced by a
similar strategy. Amplicon 1—containing exons 2–4, in-
trons 2 and 3, and the 3′ flanking sequences of exon
4—was generated by use of primers 4S and 4AS, and
primers 5S and 5AS were used to amplify the 3′ end of
intron 4 and exon 5 (amplicon 2). Primers 5S and 4AS
both contained a BglII site, which was used to combine
both amplicons. By ligation, the whole fragment (am-
plicon 3) was amplified by use of primers 6S and 6AS,
which contained a ClaI and a HindIII site, respectively.
The resulting minigene contained the 3′ end of intron 1,
exons 2–5, introns 2 and 3, and a shortened intron 4
(containing the 5′ and the 3′ ends of the intron) (fig. 1B).
DNA sequence analysis was performed to confirm the
single-base differences, at the relevant splice sites, be-
tween the minigene constructs, on the basis of normal
human genomic DNA and the DNA samples extracted
from the patients.
Analysis of the Splicing of the Pre-RNA Transcribed
from the Minigenes
The minigene constructs were transfected as diethy-
laminoethyl-dextran complexes into COS-7 cells, as de-
scribed elsewhere (Bosma et al. 1994). After 5 h, the
transfection medium was removed, and fresh medium
was added. Cells were grown for another 24 h, before
harvesting. Total RNA was isolated by use of the Qiagen
kit and reverse-transcription–primed PCR (RT-PCR)
was performed. The effect of the splice-donor–site mu-
tation was studied by use of a sense primer located at
nt 586–606 (5′-CCT CTC TCC TCT CAT TCA GAT-
3′) and an antisense primer located at nt 1138–1156 (5′-
CGC CAT TGC ATA TGC TTTC-3′). For characteri-
zation of the mRNA expressed from the minigene that
contained the splice-acceptor–site mutation, a sense pri-
mer located at nt 861–875 on exon 2 (5′-GAATTTGAA
GCC TAC-3′) and an antisense primer located at nt
1526–1546 on exon 5 (5′-TCC GGT AGC CAT AAG
Gantla et al.: Splicing Defect Causing CN-1 587
Figure 1 Location of PCR amplimers and map of expression vectors containing bilirubin-UGT1 minigenes. For patient A, primers 1S and
1AS were used to amplify the 3′ domain of exon 1 and the 5′ region of intron 1 of UGT1A1, producing amplicon 1. Primers 2S and 2AS were
used to amplify the 3′ end of intron 1, exons 2–4, and introns 2 and 3, producing amplicon 2. Amplicons 1 and 2 were digested with BglII
and ligated, to produce amplicon 3. For patient B, the 3′ end of intron 1, exons 2–4, introns 2 and 3, and the 5′ end of intron 4 were amplified
by use of amplimers 4S and 4AS (amplicon 1). Amplicon 2, consisting of the 3′ end of intron 4 and exon 5, was generated by use of amplimers
5S and 5AS. Amplimers 1 and 2 were ligated to produce amplicon 3. The primers used are as follows (“S” indicates sense, and “AS” indicates
antisense): 1S, 5′-CCT CTC TCC TCT CAT TCA GAT-3′ (exon 1); 1AS, 5′-GCT CAG CAT AGA TCT GGG GCT AG-3′ (intron 1; this primer
was designed to introduce a BglII site in the amplified product); 2S, 5′-AGA GGA AGA TCT CTA ATC ATA AC-3′ (3′ end of intron 1; this
primer was designed to introduce a BglII site in the amplified product); 2AS, 5′-CGC CAT TCG ATA TGC TTTC-3′ (3′ end of exon 4); 3S, 5′-
CTG GTT CCG GCG ACC TCT CTC CTC TCA TTC AGAT-3′ (exon 1); 3AS, 5′-CTC GCT CCG GCG ACG CCA TTG CAT ATG CTT
TC-3′ (3′ end of exon 4); 4S, 5′-CTC TAT CTC AAA CAC GCA TGCC-3′ (3′ end of intron 1); 4AS, 5′-GGA AGA TCT AAC AAC GCT ATT
AAA-3′ (5′ end of intron 4; this primer was designed to introduce a BglII site in the amplified product); 5S, 5′-GGA AGA TCT GGT AAG TCT
TCT TAA GCA GCC ATG AG-3′ (3′ end of intron 4; this primer was designed to introduce a BglII site in the amplified product); 5AS, 5′-ACC
CAC TTC TCA ATGG-3′ (3′ domain of exon 5); 6S, 5′-CCA TCG ATG TCT TAA GAG GAA GAT-3′ (spanning 3′ end of intron 1 and the 5′
end of exon 2, with a ClaI linker); and 6AS, 5′-CCC AAG CTT TCC GGT AGC CAT AAG-3′ (3′ domain of exon 5, with a HindIII linker).
CAC AAC-3′) were used. Aliquots of RT-PCR from cells
transfected with the normal and the mutated minigenes
were analyzed by electrophoresis on 2% agarose gels.
Analysis of Hepatic Bilirubin-UGT1 mRNA
Total RNA was isolated from the liver of patient B,
as described elsewhere (Chomczynski and Sacchi 1987).
RT-PCR was performed by use of the following ampli-
mers: sense (nt 1047–1067), 5′-GAT ACT TGT TAA
GTG GCT ACC-3′, and antisense (nt 1386–1406), 5′-
TTG TGC CTC ACA AAC TCC-3′. With agarose-gel
electrophoresis, amplicons of two different sizes, rep-
resenting the two alleles, were found. Both fragments
were isolated and sequenced.
Results
Mutations in the UGT1A Gene
In patient A, the nucleotide sequences of the five exons
composing UGT1A1 were completely normal. This pa-
tient, however, was homozygous for a GrC mutation
at the splice-donor site at the 5′ end of the intron 1
between exons 1 and 2 (fig. 2). Both parents were het-
erozygous for this mutation.
Patient B was a compound heterozygote. One allele
contained a CrT substitution in exon 1, at nt 145, cre-
ating a premature stop codon (data not shown). The
proband’s mother was heterozygous for this mutation.
The nucleotide sequence of the entire coding region of
the other allele was normal; instead, an ArG mutation
was present at the splice-acceptor site in intron 3 (fig.
3). The patient’s father was a heterozygous carrier of
this mutation. In both patients, all other splice-donor
and -acceptor sites, as well as branch points, had normal
nucleotide sequences.
Effect of the Intronic Mutations on Bilirubin-UGT1
RNA Processing
To determine the consequences of the splice-donor
(GrC in patient A) and the splice-acceptor (ArG in
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Figure 2 Genomic DNA sequence of the region containing the
mutation in patient A (left) and of a normal individual (right). The
nucleotide sequences are shown to the left and to the right of the gel.
Note the GrC change at the first nucleotide of the intron (the splice-
donor site) (boxed) of patient A.
Figure 3 Genomic DNA sequence of the region containing the
mutation in patient B. The mutant allele differs from the normal allele
by a n ArG single-base substitution at the splice-acceptor site (boxed).
patient B) mutations on the processing of the RNA tran-
script, COS-7 cells were transfected with normal and
mutant human bilirubin-UGT1 minigenes. A cDNA con-
taining the whole structural region of bilirubin-UGT1
also was transfected, as a control. The expressed RNA
was extracted and amplified by RT-PCR, and its nucle-
otide sequence was determined.
RT-PCR, using primers directed toward nt 586–606
(primer S) and nt 1138–1156 (primer AS), of total RNA
from cells transfected with the minigene containing the
normal splice-donor site yielded a 570-bp (nt 586–1156)
amplicon consistent with normal splicing of intron 1. In
contrast, RT-PCR of RNA isolated from cells transfected
with the minigene containing the GrC mutation in the
splice-donor site of exon 1 produced a shorter amplicon.
Sequence determination of this amplicon revealed that
a cryptic splice-donor site within exon 1 was utilized,
resulting in the deletion of 141 nt from the 3′ end of
exon 1 in the bilirubin-UGT1 mRNA (fig. 4A). The se-
quence of the cryptic splice-donor site was as follows:
GAGdGUGACU (fig. 5).
RT-PCR of the RNA isolated from the cells transfected
with the UGT1A1 miniconstruct containing the ArG
mutation at the splice-acceptor site of intron 3 (as de-
tected in patient B) also produced an amplicon shorter
than that obtained from cells transfected with the cor-
responding normal construct. Sequence determination
showed that in the mutated minigene a cryptic splice-
acceptor site within exon 4 had been utilized. The con-
text of the cryptic splice acceptor AG was as follows:
UCAGdAUUGG (fig. 5). Use of this cryptic site resulted
in the deletion of 107 nt from the 5′ end of exon 4 in
the final mRNA product (fig. 4B).
Sequence of Hepatic Bilirubin-UGT1 mRNA
Patient B had recently received a liver transplant; thus,
liver material was available for analysis. Total RNA was
isolated, and RT-PCR was performed. By amplification,
two fragments with different lengths were found. Both
fragments were isolated and sequenced. The sequence of
the longer fragment was identical to that of the normal
UGT1A1 mRNA sequence. In the shorter fragment, the
first 107 nt of exon 4 were deleted (fig. 6). Thus, in the
liver of this patient, the same cryptic splice site in
exon 4 as that identified by ex vivo expression studies
was used.
Discussion
Several UGT isoforms that are expressed from the
UGT1A locus have identical carboxy-terminal domains,
encoded by four exons located at the 3′ end of the gene
(Ritter et al. 1992a;Mackenzie et al. 1997). The amino-
terminal domains of these isoforms are encoded by single
unique exons, a series of which are located upstream of
the common-region exons. Each unique-region exon is
preceded by an independent promoter and transcrip-
tional initiation site. Thus, various lengths of pre-mRNA
are thought to be transcribed from UGT1A, by differ-
ential promoter selection (Ritter et al. 1992a). Imme-
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Figure 4 A, RT-PCR amplification of mRNA from COS-7 cells
transfected with minigene constructs. Lane a, Amplicon of mRNA
expressed from the patient A minigene. Lane b, Amplicon expressed
from the corresponding normal minigene. Lane c, Amplicon from
UGT1A1 cDNA. Lane M, Molecular size markers. Normally spliced
mRNA yielded a 570-bp amplicon, whereas in patient A the deletion
of 141 nt from exon 1 resulted in a 429-bp amplicon. B, RT-PCR
amplification of transcripts fromCOS-7 cells transfectedwithminigene
constructs. Lane a, Amplicon of the mRNA expressed from the patient
B minigene (578 bp). Lane b, Amplicon from cloned UGT1A1 cDNA
(685 bp). Lane c, Amplicon expressed form a normal minigene (685
bp). Lane M, Molecular size markers. The shorter amplicon from
mRNA expressed by the patient B minigene indicates the deletion of
107 nt.
Figure 5 Predicted splicing mechanism using cryptic splice sites,
owing to mutations at splice-donor site GrC in patient A and splice-
acceptor site ArG in patient B, and utilization of cryptic splice sites.
In patient A, 141 nt are deleted from upstream of exon 1 (A). In
patient B, 107 nt are deleted from downstream of exon 4 (B).
diately 3′ of each unique exon, there is a splice-donor
site, but there is no splice-acceptor site upstream of these
exons. Therefore, the exon located at the 5′ end of the
transcript is spliced to the first available splice-acceptor
site located 5′ of exon 2, and the entire stretch of DNA
between the exon at the 5′ end of the transcript and exon
2 is treated as an intron and is spliced out. According
to the recently adopted nomenclature, the gene is named
according to the transcription initiation site within the
UGT1A locus. For example, in the case of bilirubin-
UGT1, the transcription begins at the first unique exon
upstream of exon 2. Therefore, this gene is termed
“UGT1A1.”
In patient A, a mutation of the splice-donor site was
located immediately 3′ ofUGT1A1 exon 1. This resulted
in the utilization of a cryptic splice site within exon 1,
causing the loss of 141 nt from the 3′ end of this exon.
The abnormally spliced mRNA is predicted to result in
substitution of all amino acids at positions 241–486,
followed by a premature stop codon. A protein with
such extensive sequence abnormality may not be ex-
pressed, because of abnormal folding, or, if expressed,
is predicted to be functionally inactive. Because the
UGT1A1 exon 1 is used only in the mRNA for the
bilirubin-UGT1 isoform, other UGT isoforms expressed
from the UGT1A locus are expected to be spliced nor-
mally. The virtual absence of bilirubin glucuronides in
the bile of patient A is consistent with the observation
that only the bilirubin-UGT1 isoform contributes signif-
icantly to bilirubin glucuronidation in man (Bosma et
al. 1994).
In patient B, the splice-acceptor mutation in intron 3
resulted in the utilization of a cryptic splice site within
exon 4, causing the loss of 107 nt from the 5′ end of
this exon. The abnormally spliced mRNA is predicted
to result in the substitution of nine amino acids, at po-
sitions 262–270, followed by a premature stop codon.
This would delete the highly conserved region of the
carboxy-terminal domain of the enzyme, which is
thought to be critical for binding of the donor substrate,
UDP-glucuronic acid, thereby inactivating the enzyme.
Since exon 4 is used in all expression products of the
UGT1A locus, this lesion is expected to affect several
UGT isoforms that share exons 2–5 (Bosma et al. 1992b;
Ritter et al. 1992b). The structural mutation identified
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Figure 6 Sequence analysis of cDNA generated from hepatic
bilirubin-UGT1 mRNA from patient B. The RT-PCR products were
cloned before sequence analysis. The sequences derived from two
clones are shown, indicating the mutant sequence with the deletion of
107 nt (left) and the normal sequence (right), representing the mRNA
expressed from the other allele.
in this patient, however, was present in the unique exon
1 of the UGT1A1 gene. Thus, all other UGT isoforms
derived from the allele containing the structural muta-
tion are expected to be normal. In this patient, no bil-
irubin glucuronidating activity was present, again con-
firming that bilirubin-UGT1 is the only isoform
contributing to bilirubin glucuronidation in human liver.
Many instances in which a single-base substitution at
a splice junction resulted in abnormal splicing have been
reported (Krawczak et al. 1992). However, utilization
of a novel cryptic splice site, as a result of a mutation
at the normal splice site, has been found much less fre-
quently. Examples of human disease caused by such mu-
tations include hemophilia A and B, thalassemia B, and
Laron syndrome (Orkin et al. 1982, 1984; Goldsmith
et al. 1983; Treisman et al. 1983; Yamada et al. 1995).
Splicing of nuclear pre-mRNAs occurs through several
steps. The three sequence elements that direct this RNA
processing include the two sequence elements at the in-
tron borders and the branch site upstream of the 3′ splice
site. Initially, the 5′ splice site is cleaved, and the 5′ end
of the intron is joined to the 2′ hydroxyl of a residue in
the branch-site region of the intron. This is followed by
excision of the lariat intron and ligation of the exons.
The 5′ splice site of a pre-mRNA is recognized by U1
small nuclear ribonucleoprotein particles, through base-
pairing with the 5′ end of U1 small nuclear RNA
(snRNA) (Lerner et al. 1980; Rogers and Wall 1980).
Figure 7a shows the consensus sequence 5′-C(or A)AG
GU(A)(or G) AGU-3′, which is complementary to the
first 9 nt of the 5′ end of the U1 snRNA (in fig. 7, the
intronic bases are shown in italics). Base pairing of the
snRNA and the pre-mRNA is essential for splicing of
the pre-mRNA (Steitz et al. 1988). Natural 5′ splice-site
sequences match the consensus sequence to various ex-
tents and usually deviate from this consensus sequence
at two or three positions. The GU dinucleotide at the
cleavage site is present in almost all splice-donor sites,
and the G residue located 5′ downstream of the cleavage
site is found in 85% of cases (Steitz et al. 1988).
The GrC mutation at the splice-donor site in patient
A (fig. 7b and c) increases the mismatch with the U1
snRNA, thereby weakening the binding. In particular,
the mutation of the critical first G residue of the intron
inactivates this splice site. This results in the use of the
cryptic splice site within exon 1 (fig. 7d), which is not
used normally, because its binding to the U1 snRNA is
much weaker. However, U1 binding affinity is not the
only criterion for 5′ splice-site selection. In some situa-
tions, splicing does not occur, despite the binding of U1
snRNA to a high-affinity binding sequence. For the cryp-
tic site to be used, it must be present within a permissive
context.
In patient B, the premature stop codon present in exon
1 is predicted to truncate the bilirubin-UGT expressed
from this allele. This should reduce the bilirubin-UGT
activity by 50%. However, since Crigler-Najjar syn-
drome type 1 (CN-1; MIM 218800) is inherited as a
recessive condition, a 50% reduction of the enzyme ac-
tivity is not expected to produce a hyperbilirubinemic
phenotype. This suggested that another genetic lesion
present in the other allele prevented the expression of
functional UGT1A1 from that allele. The presence of
the ArG mutation at the 3′ splice-acceptor site in intron
3 explains the loss of expression of functionalUGT1A1,
from the second allele. The splice-acceptor–sitemutation
causes a mismatch with the 3′ end of the U1 snRNA.
Such mutations can cause skipping of the succeeding
exon or, as was seen in this case, the use of a cryptic
splice site, present within the exon, downstream of the
splice-acceptor site. The cryptic site is located probably
by a scanning mechanism that proceeds downstream
from the branch site and locates an AG pair (Steitz et
al. 1988). The AG sequence is conserved in 100% of
splice-acceptor sites. The C residue 5′ of the AG sequence
and the G residue 3′ of the AG sequence are conserved
in 80% and 60% of acceptor sites, respectively. The
normal splice acceptor had the sequence CAGG,
whereas the cryptic site had the sequence CAGA. Thus,
the cryptic acceptor site appears to be competent but is
not utilized normally, because of the stronger normal
splice site located upstream of it.
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Figure 7 5′ Splice-site sequences indicating the possible base-pairing interactions of the first 6 nt of splice-site sequences with U1 snRNA.
a, Consensus sequence. b, Normal intron 1 splice-donor site. c, Mutant intron 1 splice-donor site. d, Cryptic splice-donor site within UGT1A1
exon 1.
These two cases constitute the first report of CN-1
caused by splice-site mutations. Our results show that
the effect of the splice-site mutation on the splicing of
the pre-mRNA can be predicted on the basis of ex vivo
expression of minigene constructs. In the liver of patient
B, the same cryptic site as that identified by ex vivo
expression studies was used. This indicates that this ex
vivo expression method indeed can be used to determine
the effect of splice-site mutation on RNA processing,
without performance of a liver biopsy.
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